TGF-beta1-induced Expression of Human Mdm2 Correlates with Late-stage Metastatic Breast Cancer
Overview
Authors
Affiliations
The E3 ubiquitin ligase human murine double minute (HDM2) is overexpressed in 40%-80% of late-stage metastatic cancers in the absence of gene amplification. Hdm2 regulates p53 stability via ubiquitination and has also been implicated in altering the sensitivity of cells to TGF-beta1. Whether TGF-beta1 signaling induces Hdm2 expression leading to HDM2-mediated destabilization of p53 has not been investigated. In this study, we report that TGF-beta1-activated SMA- and MAD3 (Smad3/4) transcription factors specifically bound to the second promoter region of HDM2, leading to increased HDM2 protein expression and destabilization of p53 in human cancer cell lines. Additionally, TGF-beta1 expression led to Smad3 activation and murine double minute 2 (Mdm2) expression in murine mammary epithelial cells during epithelial-to-mesenchymal transition (EMT). Furthermore, histological analyses of human breast cancer samples demonstrated that approximately 65% of late-stage carcinomas were positive for activated Smad3 and HDM2, indicating a strong correlation between TGF-beta1-mediated induction of HDM2 and late-stage tumor progression. Identification of Hdm2 as a downstream target of TGF-beta1 represents a critical prosurvival mechanism in cancer progression and provides another point for therapeutic intervention in late-stage cancer.
Non-small cell lung cancer map and analysis: exploring interconnected oncogenic signal integrators.
Gottumukkala S, Palanisamy A Mamm Genome. 2025; .
PMID: 39939487 DOI: 10.1007/s00335-025-10110-6.
Mabry A, Singh A, Mulrooney B, Gorman J, Thielbar A, Wolf E Proc Natl Acad Sci U S A. 2024; 121(31):e2400935121.
PMID: 39047034 PMC: 11295014. DOI: 10.1073/pnas.2400935121.
Gottumukkala S, Ganesan T, Palanisamy A NPJ Syst Biol Appl. 2024; 10(1):53.
PMID: 38760412 PMC: 11101644. DOI: 10.1038/s41540-024-00378-w.
MDM2: current research status and prospects of tumor treatment.
Yao Y, Zhang Q, Li Z, Zhang H Cancer Cell Int. 2024; 24(1):170.
PMID: 38741108 PMC: 11092046. DOI: 10.1186/s12935-024-03356-8.
Li H, Shi W, Shen T, Hui S, Hou M, Wei Z Medicine (Baltimore). 2023; 102(41):e35384.
PMID: 37832105 PMC: 10578738. DOI: 10.1097/MD.0000000000035384.